Interestingly, RNA-seq-based risk score values were significantly higher in the MM cells of patients characterized by ASXL1, ATM, BRAF, DIS3, EP300, FGFR3, KMT2B, LRP1B, MAP3K1, MAX, NOTCH2, NUP214, PRDM1, PTPRD, RB1, ROS1, SETD2, TP53, TRRAP, and ZFHX3 mutations compared to patients with unmutated MM cells. This evidence concerns the gene TRRAP and Miyoshi myopathy.